These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12481710)

  • 1. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
    Clarke ML; Mackey JR; Baldwin SA; Young JD; Cass CE
    Cancer Treat Res; 2002; 112():27-47. PubMed ID: 12481710
    [No Abstract]   [Full Text] [Related]  

  • 2. [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
    Jordheim LP; Galmarini CM; Dumontet C
    Bull Cancer; 2005 Mar; 92(3):239-48. PubMed ID: 15820918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seeking the nucleoside transporter.
    Wiley JS
    Nat Med; 1997 Jan; 3(1):25-6. PubMed ID: 8986733
    [No Abstract]   [Full Text] [Related]  

  • 4. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
    Dumontet C; Fabianowska-Majewska K; Mantincic D; Callet Bauchu E; Tigaud I; Gandhi V; Lepoivre M; Peters GJ; Rolland MO; Wyczechowska D; Fang X; Gazzo S; Voorn DA; Vanier-Viornery A; MacKey J
    Br J Haematol; 1999 Jul; 106(1):78-85. PubMed ID: 10444166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
    Reiman T; Graham KA; Wong J; Belch AR; Coupland R; Young J; Cass CE; Mackey JR
    Leukemia; 2002 Sep; 16(9):1886-7. PubMed ID: 12200718
    [No Abstract]   [Full Text] [Related]  

  • 6. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
    Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
    Galmarini CM; Mackey JR; Dumontet C
    Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside analogues in the treatment of haematological malignancies.
    Johnson SA
    Expert Opin Pharmacother; 2001 Jun; 2(6):929-43. PubMed ID: 11585009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
    Hung SW; Mody HR; Govindarajan R
    Cancer Lett; 2012 Jul; 320(2):138-49. PubMed ID: 22425961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimetabolites.
    Grem JL; Takimoto CH; Multani P; Chu E; Ryan D; Chabner BA; Allegra CJ; Johnston PG
    Cancer Chemother Biol Response Modif; 1999; 18():1-38. PubMed ID: 10800475
    [No Abstract]   [Full Text] [Related]  

  • 12. Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
    Hubeek I; Peters GJ; Broekhuizen AJ; Kaspers GJ
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1513-6. PubMed ID: 15571288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine].
    Mohelníková-Duchonová B; Soucek P
    Klin Onkol; 2010; 23(5):306-10. PubMed ID: 21061681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
    Von Hoff DD; Goodwin AL; Garcia L
    Br J Cancer; 1998; 78 Suppl 3(Suppl 3):9-13. PubMed ID: 9717985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia.
    Strickland AH; Seymour C; Prince HM; Wolf M; Juneja S; Januszewicz EH
    Aust N Z J Med; 1999 Aug; 29(4):556-8. PubMed ID: 10868535
    [No Abstract]   [Full Text] [Related]  

  • 16. 2-Chlorodeoxyadenosine treatment of lymphoma.
    Saven A; Piro LD
    Cancer Treat Res; 1996; 85():15-26. PubMed ID: 9043772
    [No Abstract]   [Full Text] [Related]  

  • 17. Why do drugs work in CLL?
    Plunkett W; Begleiter A; Liliemark JO; Reed JC
    Leuk Lymphoma; 1996 Oct; 22 Suppl 2():1-11. PubMed ID: 9021705
    [No Abstract]   [Full Text] [Related]  

  • 18. Capecitabine in the management of colorectal cancer.
    Maroun JA
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):327-33. PubMed ID: 12113099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity.
    Schirmer M; Stegmann AP; Geisen F; Konwalinka G
    Exp Hematol; 1998 Dec; 26(13):1223-8. PubMed ID: 9845378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gemcitabine: from preclinic to clinic passing by pharmacokinetics].
    Lokiec F; Lansiaux A
    Bull Cancer; 2007; 94 Spec No Actualites():S85-9. PubMed ID: 17845976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.